JPH0334908A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPH0334908A JPH0334908A JP16762089A JP16762089A JPH0334908A JP H0334908 A JPH0334908 A JP H0334908A JP 16762089 A JP16762089 A JP 16762089A JP 16762089 A JP16762089 A JP 16762089A JP H0334908 A JPH0334908 A JP H0334908A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- adhesive
- adhesive protein
- adherent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 210000004907 gland Anatomy 0.000 claims abstract description 5
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 4
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 3
- 230000001070 adhesive effect Effects 0.000 claims description 28
- 239000000853 adhesive Substances 0.000 claims description 27
- 235000015170 shellfish Nutrition 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 3
- 210000004243 sweat Anatomy 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001464 adherent effect Effects 0.000 abstract 4
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241000237852 Mollusca Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000237536 Mytilus edulis Species 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000020638 mussel Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010029240 Cell-Tak Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000490567 Pinctada Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 241001455273 Tetrapoda Species 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、肌あれを改善し、美肌効果に優れた皮膚外用
剤を提供せんとするものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention aims to provide an external skin preparation that improves rough skin and has excellent skin beautifying effects.
朋あれを改善し、美肌を作る方法として、これまでいろ
いろな方法が考えられてきた。Various methods have been devised so far to improve rough skin and create beautiful skin.
まず、皮膚の代謝を促進させるため、ホルモン剤が広く
使われてきた。しかし、ホルモン剤には、副作用の恐れ
があり、その種類と配合量は厳しく制限されている。First, hormonal agents have been widely used to promote skin metabolism. However, hormonal agents may have side effects, and their types and amounts are strictly limited.
更に、皮膚の保水性を向上させるために、ヒアルロン酸
・ムコ多糖及び可)容性コラーゲンを含有する皮膚化粧
料(特公昭60−19725号)や、細胞賦活作用を活
発にさせるために、特定のアミノ酸類・ビタミン類及び
糖類の3戒分を必須成分とする皮膚外用剤(特開昭61
−289016号)や、創傷治ゆ作用を有するロズマリ
ン酸を配合した化粧料(特開昭63−162611号)
や、あるいは、糖タンパクの一種であるフィブロネクチ
ンを配合した化粧料(特開昭59−76007号)など
、いろいろと検討されて来たが、美肌を発現させるため
には、かなり長期間が必要であり、短期間で顕著な効果
を発現させるには、充分とは、言えなかった。また、細
胞増殖を促進させる物質として、フィブロネクチンの他
に、ラミニン、コラーゲン等も知られているが、今だ充
分とは11えイtい。Furthermore, in order to improve the water retention of the skin, skin cosmetics containing hyaluronic acid, mucopolysaccharide, and soluble collagen (Japanese Patent Publication No. 19725/1983), and specific cosmetics to activate the cell activation effect. External skin preparation containing the three precepts of amino acids, vitamins, and sugars as essential ingredients (JP-A-61
-289016) and cosmetics containing rosmarinic acid that has a wound-healing effect (Japanese Patent Application Laid-open No. 162611/1983).
Various studies have been conducted, such as cosmetics containing fibronectin, a type of glycoprotein (Japanese Patent Application Laid-open No. 76007/1983), but it takes a long time to develop beautiful skin. However, it could not be said that it was sufficient to produce a significant effect in a short period of time. In addition to fibronectin, laminin and collagen are also known as substances that promote cell proliferation, but they are still insufficient.
一方、皮膚に適用される接着性物質も、これまでいろい
ろ使われている。On the other hand, various adhesive substances applied to the skin have been used so far.
例えば、ビールオフタイプのパック利には、水溶↑)J
高分子のポリビニルアルコールが汎用されているが、水
分の蒸発か遅く、乾燥に時間がかかる。また、汗をかく
と、肌へのなじみが弱くなり、異和感が生じるので、新
しい、皮膜形成剤の開発がのぞまれている。また、パッ
チテス(〜用の絆創膏やパップ剤あるいはその固定用粘
着シートには、アクリル酸エステル−酢酸ビニルの共重
合体が汎用されているか、汗や水分により接着力か弱く
なり、すぐはがれたり、時として発疹、発赤、かゆみ、
かぶれなどのアレルギー性症状があられれる場合があり
、使用性が良くなかった。For example, for beer-off type packs, water-soluble ↑)J
High-molecular polyvinyl alcohol is widely used, but it evaporates water slowly and takes time to dry. In addition, when sweating, the adhesion to the skin becomes weaker, resulting in an uncomfortable feeling, so there is a need for the development of new film-forming agents. In addition, acrylic acid ester-vinyl acetate copolymers are commonly used for patch plasters, poultices, and their fixing adhesive sheets, and sweat and moisture weaken the adhesive strength, causing them to peel off easily or over time. as rash, redness, itching,
It was not easy to use, as it sometimes caused allergic symptoms such as a rash.
(発明が解決しようとする課題)
本発明者らは、朋あれを改善し、美肌を作るために、細
胞増殖効果にすぐれ、かつ水に強い接着性のある素祠を
探索し、これを皮膚外用剤に含@させて、効果の程をU
l〔かめ、bつで実使用に供することを課題とした、。(Problems to be Solved by the Invention) In order to improve rough skin and create beautiful skin, the present inventors searched for a clay that has an excellent cell proliferation effect and has strong adhesive properties against water, and applied it to the skin. Contain it in external preparations to increase its effectiveness.
l [The objective was to put it into actual use with the turtle, b.
[課題を解決するための手段〕
本弁明者らは、IIJlあれを改善し、美肌効果に優れ
た生体成分について研究して−いるが、細胞増殖効果か
あって肌のかさつきを改善し、粘着性があって肌へのな
じみが良く、しかも汗ヤ〕水分に強い接着物質を得るこ
とができた。[Means for solving the problem] The present defenders have been researching biological ingredients that can improve this problem and have excellent skin beautifying effects. We were able to obtain an adhesive substance that is flexible, blends well with the skin, and is resistant to sweat and moisture.
ヅーなわら、本発明は、接着性タンパク質を0、000
1〜0.5重量%含(7してなる1)115.5−、−
pH9,0の皮膚外用剤であり、好ましい態様とじでは
、貝類の足糸又は/及びフェノール腺から1!1られる
接着性タンパク貿であり、更に好ましい態様として(よ
、1−−−アスコルビン酸またはその誘導体を接着性タ
ンパク質の重量の1〜50倍併用することを特徴とする
皮膚外用剤である。However, in the present invention, the adhesive protein is reduced to 0,000.
Containing 1 to 0.5% by weight (1 consisting of 7) 115.5-,-
It is a skin external preparation with a pH of 9.0, and in a preferred embodiment, it is an adhesive protein derived from shellfish byssus and/or phenol glands, and in a more preferred embodiment, it is an adhesive protein derived from shellfish byssus and/or phenol glands. This is an external skin preparation characterized in that the derivative is used in combination in an amount of 1 to 50 times the weight of the adhesive protein.
以下、本発明の詳細な説明する。The present invention will be explained in detail below.
本発明で用いる接着性タンパク質とは、プロリン残基、
グリシン残基、リジン残基、チロシン残基などのアミノ
酸残基からなり、77ミノ酸配列約300〜1200の
粘着性を有する接着性タンパク質である。The adhesive protein used in the present invention includes proline residues,
It is an adhesive protein consisting of amino acid residues such as glycine residues, lysine residues, and tyrosine residues, and has a 77 amino acid sequence of approximately 300 to 1200 amino acids.
尚、接着性タンパク質は、軟体動物閂二枚貝網翼形目イ
ノjイ斜のムラザキイカイ、ニジイガイやラグイスガイ
斜のラグイスガイ、アコヤガイなど足糸を有する貝類及
び微生物由来のものが適している。Suitable adhesive proteins are those derived from shellfish having byssus threads, such as molluscs, bivalves, molluscs, molluscs of the order Pteromorpha, molluscs such as the purple mussel, the rainbow mussel, the lagoon oyster, and the pearl oyster, as well as from microorganisms.
以下、エンゲブレトソンの方法(G、H,Enaebr
etson at at、、 Comp、 Bioch
em、 Physiol、、 77B[1]、201(
1984)、 )を参考に、ムラザキイ力イの足糸か
ら接着性タンパク質を製造する方法について述べる。Below, the method of Engebretson (G, H, Enaebr)
etson at at, Comp, Bioch
em, Physiol, 77B[1], 201(
1984), ), we will describe a method for producing adhesive proteins from the byssus threads of Murazakii.
ムラザキイノj”イは、テトラポットやコンクリート護
岸などにびっしりと群生している黒つぼい貝であり(坂
ロ勇、電力中央研究所生物研究所伺究報告、 No、4
85024. P、 1〜17(1986)、 )、こ
れを採取する。足糸は、幹・糸・粘@盤から構成されて
いるが、これらを貝から切りはなし、海水で洗い、小石
などの夾雑物を除く。Murazakii Inoj”i is a black-shelled shellfish that grows in dense clusters in tetrapods and concrete seawalls (Isamu Sakaro, Research Report of Biological Research Institute, Central Research Institute of Electric Power Industry, No. 4)
85024. P, 1-17 (1986), ). The byssus consists of a trunk, thread, and sticky disk, which are cut from the shell and washed with seawater to remove foreign substances such as pebbles.
足糸全0.05M ト1)スー塩M (pH7,5)
、1,0M食塩、0.001 Mぶつ化フェニルメヂル
スルボル、0.01M N=エヂルマレイミド、0.
025Mエチレンジアミン4酢醸からなるタンパク分解
酵素阻害液中に保存する。足糸をとり出し、4Mグアニ
ジン塩酸と0.1M1〜リス(こ塩酸をガロえてpH7
,2に調製した溶液で洗浄し、次いて足糸をこの溶液に
浸漬し、5°C・48時間抽出を行う。遠心分離機で−
[澄液と残渣分にわける(20,000 xQ) 。残
渣分を0.5M酢酸水溶液中に分散させ、ペプシンを加
え、5°C・48時間タンパク質の消化を行う。Byssus total 0.05M 1) Sue salt M (pH 7,5)
, 1.0M common salt, 0.001M butylated phenylmedyl sulfol, 0.01M N=edilmaleimide, 0.01M salt.
Stored in a proteolytic enzyme inhibitor solution consisting of 025M ethylenediamine 4 vinegar. Take out the byssus and mix it with 4M guanidine hydrochloric acid and 0.1M 1~lisu (pH 7).
, 2. Then, the bysulia is immersed in this solution and extracted at 5°C for 48 hours. In a centrifuge
[Divided into clear liquid and residue (20,000 x Q). The residue is dispersed in a 0.5M acetic acid aqueous solution, pepsin is added, and the protein is digested at 5°C for 48 hours.
遠心分離機で上澄液と残渣分にわ(プる(20.000
XG)。上澄液をゲルクロマトグラフィー(セファデッ
クスG−150〉法にて分画し、分子量約15,000
〜150.000の画分を回収することで、ペプシン消
化接着性タンパク貿を得る。Separate the supernatant and residue using a centrifuge (20,000
XG). The supernatant was fractionated by gel chromatography (Sephadex G-150), and the molecular weight was approximately 15,000.
Pepsin-digested adhesive protein fractions are obtained by collecting fractions of ~150.000.
尚、ウェイトの方法(」。旧Waite、 J、BiO
IOgical Chemistry、258[5L2
911(1983)、及び米国特許第4.687.74
0号)を参考に、ムラザキイガイのフェノール腺から、
]・リブシン消化接着性タンパク質を得ることもできる
。Furthermore, Waite's method (formerly Waite, J., BiO
IOgical Chemistry, 258 [5L2
911 (1983), and U.S. Patent No. 4.687.74.
0), from the phenol glands of the purple mussel,
]・It is also possible to obtain an adhesive protein by digesting ribsin.
また、本発明で用いる接着性タンパク貿とは、市販のも
のから入手することも可能であり、例えば、パイオボリ
マーズ社(B10PO1yIIlerS、InC1)製
のセルタック(Cel l−丁ak)が挙げられる。Further, the adhesive protein used in the present invention can be obtained from commercially available products, such as CellTak manufactured by Piobolimers (B10PO1yIIlerS, InC1).
更に、組換えDNA法の技術を使い、微生物(大腸菌、
枯草菌、酵母)を宿主として製造される生物接着タンパ
ク質(特開昭61−85400 @ )も利用すること
ができる。Furthermore, using recombinant DNA technology, microorganisms (E. coli,
Bioadhesion proteins produced using Bacillus subtilis, yeast) as hosts (Japanese Patent Application Laid-open No. 61-85400@) can also be used.
これら接着性タンパク質は、中性附近で安定であり、p
H5,5〜pH9,0で使用できるが、特にpt+e、
5〜pH8,0が適している。肌あれ改善を目的に、こ
れら接着性タンパク質をo、 oooi〜0.5量%使
用する。o、 oooi重量%より低濃度なら効果が期
待できず、0.5重量%を超えると特異臭が強くなり、
いずれも好ましくない。These adhesive proteins are stable near neutrality and p
It can be used at pH 5.5 to pH 9.0, but especially pt+e,
5 to pH 8.0 is suitable. For the purpose of improving rough skin, these adhesive proteins are used in amounts of o, oooi to 0.5% by weight. o, oooi If the concentration is lower than 0.5% by weight, no effect can be expected, and if it exceeds 0.5% by weight, the specific odor will be strong.
Neither is preferable.
次に、本発明で用いるL−アスコルビン酸またはその誘
導体とは、ビタミンC群のことであり、特に「−アスコ
ルビン酸リン酸エステル・マグネシウム塩(以下、AP
と称する〉が好ましい。Next, the L-ascorbic acid or its derivative used in the present invention refers to the vitamin C group, and especially "-ascorbic acid phosphate ester magnesium salt (hereinafter referred to as AP
〉 is preferred.
接着剤タンパク質とビタミンC群とを併用することによ
り、接着性タンパク質の安定性を高めるとともに美肌効
果を更に高めることができる。ビタミンC群の量が接着
性タンパク質の重量より低いと接着性タンパク質の安定
性を高める効果が低くなり、また、ビタミンC群の量が
接着性タンパク質の重量の50倍を超えると、接着性タ
ンパク質の安定化のためには過剰となり、所期の目的か
らして無駄となる。By using the adhesive protein and vitamin C group together, the stability of the adhesive protein can be increased and the skin beautifying effect can be further enhanced. If the amount of the vitamin C group is lower than the weight of the adhesive protein, the effect of increasing the stability of the adhesive protein will be reduced, and if the amount of the vitamin C group exceeds 50 times the weight of the adhesive protein, the adhesive protein This would be excessive for the purpose of stabilizing the system, and would be wasteful for the intended purpose.
次に、本発明の実施例と比較対照のための比較例につい
て、処方と製法を記す。Next, the formulations and manufacturing methods of Examples of the present invention and Comparative Examples for comparison will be described.
尚、配合割合は重量部である。Incidentally, the blending ratio is in parts by weight.
実施例1と比較例1の栄養乳液について処方をまとめて
表1に示す。The formulations of the nutritional emulsions of Example 1 and Comparative Example 1 are summarized in Table 1.
(製法〉
ホモミキザー(こ■を入れ、室温にて撹拌し、均一に溶
解する。これに、撹拌しなから■を加えて乳化を行う。(Manufacturing method) Add ① to a homomixer and stir at room temperature to dissolve uniformly. Add ① to this while stirring to emulsify.
次いで、■を加えて中和する。Next, add ■ to neutralize.
その後■を加え均一乳化物とする。After that, add ■ to make a homogeneous emulsion.
容器につめて冷暗所に保存する。Pack into a container and store in a cool, dark place.
実施例2. 用時調製型化粧水
(処方)
(製法)
■を室温にて攪拌して均一に可溶化し、化粧水口とする
。Example 2. Ready-to-use lotion (prescription) (manufacturing method) Stir ① at room temperature to uniformly solubilize it and use it as a lotion.
■を低速で混合し、粉末1とする。Mix (2) at low speed to obtain powder 1.
(使用法)
■の粉末口を適量手のひらにとり、■の化粧水1を加え
て指でよく混ぜる。これを肌に塗布し、よく伸ばして使
用する。(How to use) Take an appropriate amount of the powder (■) in the palm of your hand, add 1 part of the lotion (■), and mix well with your fingers. Apply this to your skin and spread it well.
実施例3. ビールオフ型 パック料(処方) 1.3 ブチレングリ=1 ル パラオキシ安息’a Mメチル (製法) ■を室温にて分散溶解させる。Example 3. Beer-off type pack fee (prescription) 1.3 Butylene glycol = 1 le paraoxyben'a M methyl (Manufacturing method) Disperse and dissolve (2) at room temperature.
これに■を加えてよく随伴する。This is often accompanied by ■.
容器につめて製品とする。Pack it into a container and use it as a product.
(発明の効果)
本発明品がl]Itあれを改善し、美月几効果に浸れた
皮膚外用剤であることについて詳述する。(Effects of the Invention) The fact that the product of the present invention is a skin preparation for external use that improves 1] It and is immersed in the Mitsuki effect will be described in detail.
(1)美肌効果
く実験方法と結果〉
2
(試料〉
本発明晶]及び比較品口
(試験法)
老人性乾皮症を呈づる被験者16名を抽出し、それぞれ
無作為にA群(8名)、8群(8名)に分(ブ、A f
ilには本発明品1を8群には比較量1を1日2回(朝
・ダ)2ケ月間使用してもらい、2ケ月後の肌の状態を
肉眼で碧察した。(1) Experimental method and results for skin beautification effect> 2 (Sample) Crystal of the present invention and comparative product (Test method) 16 subjects exhibiting senile xeroderma were selected, and each was randomly assigned to Group A (8 ), divided into 8 groups (8 people) (B, A f
Group 8 was asked to use Invention Product 1 twice a day (morning and daytime) for 2 months, and the skin condition was visually observed after 2 months.
(評[i >
41−4−:はとんど荒れが回復
−+−+ :かなり荒れが回復
十:やや荒れが回復
:変化なし
く結果)
表2より明らかなように、本発明品には、月nあれを改
善し、矢車1効果に優れていることがわかる。(Evaluation [i > 41-4-: Most of the roughness has recovered -+-+: Much of the roughness has recovered 10: Somewhat of the roughness has recovered: No change results) As is clear from Table 2, the product of the present invention It can be seen that this method improves Tsuki n Are and is superior to Yaguruma 1 effect.
(2)l]11あれ改善効果
く実験方法と結果〉
(試料〉
本発明品1及び比較量1
(試験法)
乾性肌又は荒れ性1letの女性20名をパネラとし、
左手の甲全面に比較量1を、右手の甲全面に本発明品1
をそれぞれ1日2回(朝・夕)よく伸しながら塗イトし
、これを20日間続けた後、表3に示ずような評価項目
についで美容専門家に5点法にて評(mlシてもらった
。(2) l] 11 Improvement Effects Experimental Methods and Results> (Samples) Invention Product 1 and Comparative Amount 1 (Test Method) A panel of 20 women with dry or rough skin 1 let.
Comparative amount 1 was applied to the entire back of the left hand, and inventive product 1 was applied to the entire back of the right hand.
Apply each twice a day (morning and evening), stretching well, and after applying this for 20 days, a beauty expert will evaluate the evaluation items shown in Table 3 on a 5-point scale (ml I received it.
全パネラ−について、平均点を表4に示ず。Average scores for all panelists are not shown in Table 4.
(以下余白)
(評価)
(結果)
表4より明らかなように、本発明の栄養乳液は、皮膚に
連用することにより、いずれの項目においても高得点で
あり、所期の目的を達して5
いる。(Left space below) (Evaluation) (Results) As is clear from Table 4, the nutritional emulsion of the present invention, when used repeatedly on the skin, achieved high scores in all items and achieved the intended purpose. There is.
一方、 接着性タンパク質を含有していない比 較量1は、 かさつきと小じわの項目で改善の度 合いが低い。on the other hand, Ratio without adhesive proteins Calibration amount 1 is Degree of improvement in dryness and fine wrinkles The match is low.
Claims (1)
有してなるpH5.5〜pH9.0の皮膚外用剤。 2)接着性タンパク質が、貝類の足糸又は/及びフエー
ノール腺から得られる請求項1)記載の皮膚外用剤。 3)L−アスコルビン酸またはその誘導体を、接着性タ
ンパク質の重量の1〜50倍併用することを特徴とする
請求項1)、2)記載の皮膚外用剤。[Scope of Claims] 1) An external preparation for skin having a pH of 5.5 to 9.0 and containing 0.0001 to 0.5% by weight of an adhesive protein. 2) The skin external preparation according to claim 1), wherein the adhesive protein is obtained from the byssus and/or phenolic glands of shellfish. 3) The skin external preparation according to claim 1) or 2), characterized in that L-ascorbic acid or a derivative thereof is used in an amount of 1 to 50 times the weight of the adhesive protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1167620A JP2808307B2 (en) | 1989-06-29 | 1989-06-29 | External preparation for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1167620A JP2808307B2 (en) | 1989-06-29 | 1989-06-29 | External preparation for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0334908A true JPH0334908A (en) | 1991-02-14 |
| JP2808307B2 JP2808307B2 (en) | 1998-10-08 |
Family
ID=15853165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1167620A Expired - Fee Related JP2808307B2 (en) | 1989-06-29 | 1989-06-29 | External preparation for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2808307B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07238010A (en) * | 1994-02-24 | 1995-09-12 | Kanebo Ltd | Skin cosmetic |
| JP2006520389A (en) * | 2003-03-14 | 2006-09-07 | フードサイエンス、コーポレイション | Method for treating cancer using PERNACANALICULUS component and PERNACANALICULUS extract |
| JP2023078503A (en) * | 2021-11-26 | 2023-06-07 | 御木本製薬株式会社 | Skin topical agent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS49134816A (en) * | 1973-04-27 | 1974-12-25 | ||
| JPS5976007A (en) * | 1982-10-22 | 1984-04-28 | Shiseido Co Ltd | Cosmetic |
| JPS61238712A (en) * | 1985-04-17 | 1986-10-24 | Shiseido Co Ltd | Skin cosmetic |
| JPS6357507A (en) * | 1986-08-28 | 1988-03-12 | Mikimoto Seiyaku Kk | Production of cosmetic raw material |
-
1989
- 1989-06-29 JP JP1167620A patent/JP2808307B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS49134816A (en) * | 1973-04-27 | 1974-12-25 | ||
| JPS5976007A (en) * | 1982-10-22 | 1984-04-28 | Shiseido Co Ltd | Cosmetic |
| JPS61238712A (en) * | 1985-04-17 | 1986-10-24 | Shiseido Co Ltd | Skin cosmetic |
| JPS6357507A (en) * | 1986-08-28 | 1988-03-12 | Mikimoto Seiyaku Kk | Production of cosmetic raw material |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07238010A (en) * | 1994-02-24 | 1995-09-12 | Kanebo Ltd | Skin cosmetic |
| JP2006520389A (en) * | 2003-03-14 | 2006-09-07 | フードサイエンス、コーポレイション | Method for treating cancer using PERNACANALICULUS component and PERNACANALICULUS extract |
| JP2023078503A (en) * | 2021-11-26 | 2023-06-07 | 御木本製薬株式会社 | Skin topical agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2808307B2 (en) | 1998-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6337389B1 (en) | Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof | |
| JPH07274977A (en) | Extraction method of useful plant extract, plant extract obtained by the extraction method, and skin improving article containing the plant extract as an active ingredient | |
| US8877713B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
| CN104884074B (en) | Use of flax extract derived from the hydrolysis of flax protein as an active antimicrobial agent | |
| CN115554187B (en) | A mussel mucin skin repair emulsion that can be sterilized by moist heat and its preparation method | |
| CN109276515A (en) | A kind of composition and the preparation method and application thereof containing biological active collagen peptide | |
| JPH10182412A (en) | External-use medical preparation | |
| CN101172095A (en) | Cosmetics material of protolysate containing royal jelly | |
| JP2012514626A (en) | Novel anti-aging peptide and cosmetic and / or pharmaceutical composition containing the same | |
| JPS59134706A (en) | Cosmetic | |
| CN110522709A (en) | Skin care compositions and uses thereof | |
| CN116712372A (en) | Anti-wrinkle firming composition and preparation method thereof | |
| JP2000309521A (en) | Skin lotion | |
| CN111632002A (en) | Whitening anti-inflammatory composition and application and preparation method thereof | |
| WO2002064104A1 (en) | Methods for treating fingernails and toenails | |
| CN110123666A (en) | A kind of multiple-effect maintenance freeze-drying film | |
| JPH0334908A (en) | External preparation for skin | |
| JPS6253909A (en) | Cosmetic containing water-soluble hydrolyzate of vegetable seed protein | |
| WO2025112864A1 (en) | Mild anti-aging composition containing recombinant collagen and use thereof | |
| CN110897991B (en) | Lip gloss with skin care function and preparation method thereof | |
| JPH01275511A (en) | External drug for skin | |
| CN119139149A (en) | Moisturizing light-grain composition containing recombinant collagen and application thereof | |
| JP2834278B2 (en) | Cosmetic and external preparation for skin | |
| JPS61238712A (en) | Skin cosmetic | |
| JP2895572B2 (en) | Cosmetic and external preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |